Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler

NCT01257048 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD Method Evaluation
Chronic Obstructive Pulmonary Disease Method Evaluation

Interventions

DRUG: Formoterol Turbuhaler
DRUG: Budesonide/Formoterol Turbuhaler
DRUG: Formoterol Turbuhaler

Sponsor

AstraZeneca